Search Results - "WIJDENES, John"
-
1
Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth
Published in Haematologica (Roma) (01-02-2017)“…Interleukin-6 has an important role in the pathophysiology of multiple myeloma where it supports the growth and survival of the malignant plasma cells in the…”
Get full text
Journal Article -
2
Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells
Published in Blood (01-12-2004)“…We tested the in vitro and in vivo antitumor activity of the maytansinoid DM1 (N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine), a potent antimicrotubule…”
Get full text
Journal Article -
3
Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
Published in EJNMMI research (01-09-2011)“…Background Overexpression of syndecan-1 (CD138) in breast carcinoma correlates with a poor prognosis and an aggressive phenotype. The objective of this study…”
Get full text
Journal Article -
4
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
Published in British journal of haematology (01-08-1996)“…We developed a new monoclonal antibody. B-B4, which specifically identifies human plasma cells. It strongly reacts with all multiple myeloma cell lines and…”
Get more information
Journal Article -
5
Expression of Interleukin 13 Receptor in Glioma and Renal Cell Carcinoma: IL13Rα2 as a Decoy Receptor for IL13
Published in Laboratory investigation (01-09-2001)“…Glioma and renal cell carcinoma (RCC) cells express high affinity interleukin 13 (IL13) binding sites, but only RCC cell proliferation was inhibited by IL13…”
Get full text
Journal Article -
6
Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses
Published in The Journal of immunology (1950) (01-12-1998)“…Soluble receptors for several cytokines have been detected in body fluids and are believed to modulate the cytokine response by binding the ligand and thereby…”
Get full text
Journal Article -
7
Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody
Published in The New England journal of medicine (03-03-1994)“…Castleman's disease (angiofollicular lymphoid hyperplasia) is a heterogeneous group of lymphoproliferative disorders of uncertain cause 1 . Two pathologic…”
Get full text
Journal Article -
8
The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells
Published in British journal of haematology (01-03-1998)“…Syndecan‐1 is a cell membrane proteoglycan that binds extracellular matrix components and various growth factors. It is expressed only on malignant plasma…”
Get full text
Journal Article -
9
Characterization of monoclonal antibodies directed against trail or trail receptors
Published in Cellular Immunology (01-07-2005)“…A subset of tumour necrosis factor receptor family members is involved in death transducing signals and is, therefore, referred as the “death receptors.”…”
Get full text
Journal Article -
10
Interleukin-6 Family of Cytokines Induced Activation of Different Functional Sites Expressed by gp130 Transducing Protein
Published in The Journal of biological chemistry (21-06-1996)“…Gp130 transducing protein was shown to be involved in the formation of the high affinity receptors for interleukin 6 (IL-6), interleukin-11 (IL-11), leukemia…”
Get full text
Journal Article -
11
Studies on the Interleukin-6-type Cytokine Signal Transducer gp130 Reveal a Novel Mechanism of Receptor Activation by Monoclonal Antibodies
Published in The Journal of biological chemistry (18-02-2000)“…The transmembrane glycoprotein gp130 belongs to the family of hematopoietic cytokine receptors. It represents the common signal transducing receptor component…”
Get full text
Journal Article -
12
The Immunoglobulin-like Module of gp130 Is Required for Signaling by Interleukin-6, but Not by Leukemia Inhibitory Factor
Published in The Journal of biological chemistry (28-08-1998)“…The transmembrane protein gp130 is a shared component of the receptor complexes for the interleukin-6 (IL-6)-type cytokines, which include IL-6, leukemia…”
Get full text
Journal Article -
13
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo
Published in European journal of immunology (01-11-1992)“…A patient with plasma cell leukemia was treated with anti-interleukin (IL)-6 monoclonal antibodies (mAb) for 2 months. Using chromatography on protein…”
Get more information
Journal Article -
14
Cyclosporin A inhibition of macrophage colony-stimulating factor (M-CSF) production by activated human T lymphocytes
Published in Journal of leukocyte biology (01-02-2002)“…M‐CSF is a pleiotropic cytokine involved in the survival, proliferation, and differentiation of cells of the monocyte/macrophagelineage. M‐CSF is produced by…”
Get full text
Journal Article -
15
Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function
Published in Blood (01-09-2007)“…CD4+CD25+Foxp3+ regulatory T cells (CD25+ Treg cells) direct the maintenance of immunological self-tolerance by active suppression of autoaggressive T-cell…”
Get full text
Journal Article -
16
IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner
Published in The Journal of immunology (1950) (01-07-2016)“…NK cells are critical for innate immunity-mediated protection. The main roles of NK cells rely on their cytotoxic functions or depend on the tuning of Th1…”
Get full text
Journal Article -
17
Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M
Published in Journal of immunological methods (28-03-1996)“…Five cytokines activate the gp130 IL-6 transducer: ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor and oncostatin M…”
Get full text
Journal Article -
18
Clinical and biologic effects of anti–interleukin‐10 monoclonal antibody administration in systemic lupus erythematosus
Published in Arthritis and rheumatism (01-08-2000)“…Objective To evaluate the safety and clinical efficacy of administering an anti–interleukin‐10 (anti–IL‐10) monoclonal antibody (mAb) to systemic lupus…”
Get full text
Journal Article -
19
Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics
Published in Protein engineering, design and selection (01-04-2016)“…Abstract Highly potent human antibodies are required to therapeutically neutralize cytokines such as interleukin-6 (IL-6) that is involved in many inflammatory…”
Get full text
Journal Article -
20
A new anti-mesothelin antibody targets selectively the membrane-associated form
Published in mAbs (03-04-2017)“…Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that shows promise as a target for antibody-directed cancer therapy. High levels…”
Get full text
Journal Article